脂蛋白(a)在冠心病诊疗中的研究进展
Research Progress of Lipoprotein(a) in the Diagnosis and Treatment of Coronary Heart Disease
DOI: 10.12677/acm.2025.1572080, PDF,   
作者: 梁元斌：黑龙江中医药大学研究生院，黑龙江 哈尔滨；刘 莉*：黑龙江中医药大学附属第一医院心血管病科，黑龙江 哈尔滨
关键词: 脂蛋白(a)；冠心病；研究进展；Lipoprotein(a)； Coronary Heart Disease； Research Progress
摘要: 冠心病对人类健康威胁极大，而血脂异常被认为是冠心病的主要危险因素之一。脂蛋白(a) [LP(a)]是一种特殊的脂蛋白颗粒，LP(a)水平升高可显著增加冠心病发生发展的风险。随着人们对LP(a)研究的深入，LP(a)的代谢途径、致病机制及治疗手段受到广泛关注。本文将对Lp(a)的结构、代谢途径、流行病学、致病机制、与冠心病的相关性及其治疗进行综述。
Abstract: Coronary heart disease represents a substantial threat to human health, with dyslipidemia being one of its primary risk factors. Lipoprotein(a) [LP(a)] is a unique form of lipoprotein particle. High levels of LP(a) are associated with a marked increase in the risk of developing and progressing coronary heart disease. As research on LP(a) advances, its metabolic pathways, disease-causing mechanisms, and therapeutic approaches have garnered significant interest. This paper aims to provide an overview of the structure, metabolism, epidemiology, pathogenic mechanisms, association with coronary heart disease, and treatment strategies for LP(a).
文章引用：梁元斌, 刘莉. 脂蛋白(a)在冠心病诊疗中的研究进展[J]. 临床医学进展, 2025, 15(7): 973-977. https://doi.org/10.12677/acm.2025.1572080

参考文献

[1] 中国心血管健康与疾病报告2023概要[J]. 中国循环杂志, 2024, 39(7): 625-660.
[2] Berg, K. (1965) A New Serum Type System in Man—The LD System. Vox Sanguinis, 10, 513-527. [Google Scholar] [CrossRef] [PubMed]
[3] Kamstrup, P.R., TybjŠrg-Hansen, A. and Steffensen, R. (2009) Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA, 301, 2331-2339. [Google Scholar] [CrossRef] [PubMed]
[4] Doi, T., Langsted, A. and Nordestgaard, B.G. (2023) Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans. Journal of Atherosclerosis and Thrombosis, 30, 1525-1546. [Google Scholar] [CrossRef] [PubMed]
[5] Cegla, J., Neely, R.D.G., France, M., Ferns, G., Byrne, C.D., Halcox, J., et al. (2019) HEART UK Consensus Statement on Lipoprotein(a): A Call to Action. Atherosclerosis, 291, 62-70. [Google Scholar] [CrossRef] [PubMed]
[6] Gencer, B., Kronenberg, F., Stroes, E.S. and Mach, F. (2017) Lipoprotein(a): The Revenant. European Heart Journal, 38, 1553-1560. [Google Scholar] [CrossRef] [PubMed]
[7] Tsimikas, S. (2017) A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69, 692-711. [Google Scholar] [CrossRef] [PubMed]
[8] Hofmann, S.L., Eaton, D.L., Brown, M.S., McConathy, W.J., Goldstein, J.L. and Hammer, R.E. (1990) Overexpression of Human Low Density Lipoprotein Receptors Leads to Accelerated Catabolism of Lp(a) Lipoprotein in Transgenic Mice. Journal of Clinical Investigation, 85, 1542-1547. [Google Scholar] [CrossRef] [PubMed]
[9] Utermann, G., Hoppichler, F., Dieplinger, H., Seed, M., Thompson, G. and Boerwinkle, E. (1989) Defects in the Low Density Lipoprotein Receptor Gene Affect Lipoprotein (a) Levels: Multiplicative Interaction of Two Gene Loci Associated with Premature Atherosclerosis. Proceedings of the National Academy of Sciences, 86, 4171-4174. [Google Scholar] [CrossRef] [PubMed]
[10] Trenkwalder, E., Gruber, A., König, P., Dieplinger, H. and Kronenberg, F. (1997) Increased Plasma Concentrations of LDL-Unbound Apo(a) in Patients with End-Stage Renal Disease: Rapid Communication. Kidney International, 52, 1685-1692. [Google Scholar] [CrossRef] [PubMed]
[11] Kovesdy, C.P., Astor, B.C., Longenecker, J.C. and Coresh, J. (2002) Association of Kidney Function with Serum Lipoprotein(a) Level: The Third National Health and Nutrition Examination Survey (1991-1994). American Journal of Kidney Diseases, 40, 899-908. [Google Scholar] [CrossRef] [PubMed]
[12] Man, S., Zu, Y., Yang, X., Deng, Y., Shen, D., Ma, Y., et al. (2025) Prevalence of Elevated Lipoprotein(a) and Its Association with Subclinical Atherosclerosis in 2.9 Million Chinese Adults. Journal of the American College of Cardiology, 85, 1979-1992. [Google Scholar] [CrossRef] [PubMed]
[13] Cantin, B., Després, J., Lamarche, B., Moorjani, S., Lupien, P.J., Bogaty, P., et al. (2002) Association of Fibrinogen and Lipoprotein(a) as a Coronary Heart Disease Risk Factor in Men (the Quebec Cardiovascular Study). The American Journal of Cardiology, 89, 662-666. [Google Scholar] [CrossRef] [PubMed]
[14] Sotiriou, S.N., Orlova, V.V., Al‐Fakhri, N., Ihanus, E., Economopoulou, M., Isermann, B., et al. (2006) Lipoprotein(a) in Atherosclerotic Plaques Recruits Inflammatory Cells through Interaction with Mac‐1 Integrin. The FASEB Journal, 20, 559-561. [Google Scholar] [CrossRef] [PubMed]
[15] Di Fusco, S.A., Arca, M., Scicchitano, P., Alonzo, A., Perone, F., Gulizia, M.M., et al. (2022) Lipoprotein(a): A Risk Factor for Atherosclerosis and an Emerging Therapeutic Target. Heart, 109, 18-25. [Google Scholar] [CrossRef] [PubMed]
[16] Reaven, G. (2002) Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular Disease. Circulation, 106, 286-288. [Google Scholar] [CrossRef] [PubMed]
[17] Labudovic, D., Kostovska, I., Tosheska Trajkovska, K., Cekovska, S., Brezovska Kavrakova, J. and Topuzovska, S. (2019) Lipoprotein(a)—Link between Atherogenesis and Thrombosis. Prague Medical Report, 120, 39-51. [Google Scholar] [CrossRef] [PubMed]
[18] Schmidt, K., Noureen, A., Kronenberg, F. and Utermann, G. (2016) Structure, Function, and Genetics of Lipoprotein(a). Journal of Lipid Research, 57, 1339-1359. [Google Scholar] [CrossRef] [PubMed]
[19] 石艳璞, 曹晔萱, 靳景璐, 等. 血浆脂蛋白(a)浓度与青年人群冠心病关系的横断面研究[J]. 中国循环杂志, 2020, 35(4): 343-348.
[20] Leistner, D.M., Laguna-Fernandez, A., Haghikia, A., Abdelwahed, Y.S., Schatz, A., Erbay, A., et al. (2024) Impact of Elevated Lipoprotein(a) on Coronary Artery Disease Phenotype and Severity. European Journal of Preventive Cardiology, 31, 856-865. [Google Scholar] [CrossRef] [PubMed]
[21] 李世雨, 张星, 胡文立. 脂蛋白(a)与颈动脉粥样硬化不稳定斑块的关系[J]. 中国卒中杂志, 2024, 19(5): 539-544.
[22] 郝岩, 潘洋, 高洪瑞, 等. 术前血清脂蛋白a和低密度脂蛋白胆固醇预测急性冠状动脉综合征患者PCI术后短期不良预后价值的比较[J]. 临床心血管病杂志, 2020, 36(12): 1115-1119.
[23] 王增武, 刘静, 李建军, 等. 中国血脂管理指南(2023年) [J]. 中国循环杂志, 2023, 38(3): 237-271.
[24] 胡祎瑄, 周子凯. 反义寡核苷酸药物在神经系统疾病治疗中的研究与应用[J]. 中国医药导刊, 2024, 26(4): 345-352.
[25] Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J., Baum, S.J., Steinhagen-Thiessen, E., et al. (2020) Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine, 382, 244-255. [Google Scholar] [CrossRef] [PubMed]
[26] Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B.R., Strahs, A., Clausen, V., et al. (2017) A Highly Durable Rnai Therapeutic Inhibitor of PCSK9. New England Journal of Medicine, 376, 41-51. [Google Scholar] [CrossRef] [PubMed]
[27] Rosenson, R.S., López, J.A.G., Gaudet, D., Baum, S.J., Stout, E., Lepor, N.E., et al. (2025) Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results from the OCEAN (a)-DOSE Trial. JAMA Cardiology, 10, Article No. 482. [Google Scholar] [CrossRef] [PubMed]
[28] 邓凤琳, 代海兵, 鄢盛恺. 脂蛋白(a)的临床测定与应用进展[J]. 中国心血管杂志, 2024, 29(5): 492-495.
[29] Nicholls, S.J., Ni, W., Rhodes, G.M., Nissen, S.E., Navar, A.M., Michael, L.F., et al. (2025) Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA, 333, 222-231. [Google Scholar] [CrossRef] [PubMed]

为你推荐